IP Library Granted Patent US 8,388,668
Granted Patent B2
US 8,388,668 · App. 11/197,869 · Granted Mar 5, 2013

Methods to regulate polarization of excitable cells

Inventor: Gholam A. Peyman (New Orleans, LA)
Assignee: Gholam A. Peyman
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,388,668
App. No.
11/197,869
Granted
Mar 5, 2013
Kind
B2
Abstract

Minimally invasive delivery with intercellular and/or intracellular localization of nano- and micro-particle solar cells within and among excitable biological cells to controllably regulate membrane polarization of such cells. The cells include retinal and other sensory cells, muscle cells, and nerve cells.

Claims (18)

1. A method to controllably regulate plasma membrane polarization of a functional retinal cell excitable by light but having abnormal membrane polarization, the method comprising the steps of

administering a plurality of quantum dots mixed into or with a biocompatible fluid to an eye of a patient in need thereof, the eye having a light-excitable functional retinal cell having abnormal membrane polarization,

applying light to the quantum dots under conditions sufficient to controllably activate the quantum dots to controllably regulate the plasma membrane polarization of the light-excitable retinal cell by the activated quantum dots, and

monitoring the altered plasma membrane polarization for at least one of a normal polarization state, a repolarized state, a hyperpolarized state, or a hypopolarized state.

2. The method of claim 1 further comprising selectively regulating polarization in areas of the cell bound by occluding junctions by regulating the site of exposure.

3. The method of claim 1 wherein the patient in need thereof has a degenerative disease of the retinal cell.

4. The method of claim 1 wherein at least one of the time of exposure or intensity of exposure of the light is increased from an initial time or intensity so that the regulated plasma membrane polarization of the retinal cell is propagated to at least a second retinal cell.

5. The method of claim 1 wherein the administering step further comprises administering sensor-containing quantum dots sensitive to at least one physiologic parameter of a patient, and the monitoring step further comprises monitoring data from the sensors to further provide at least one physiologic parameter in the patient.

6. The method of claim 1 wherein the light applied is at least one of ambient light, ultraviolet light, visible light, or infrared light.

7. A method to controllably regulate plasma membrane polarization of at least one functional abnormally polarized retinal cone or rod cell excitable by light, the method comprising the steps of

providing a plurality of quantum dots to a vitreous cavity of an eye of a patient in need thereof, the eye also having a plurality of biological cells comprising a retina, the quantum dots provided in a fluid sufficient to diffusively disseminate the quantum dots substantially throughout the retinal cells,

applying light to the quantum dots under conditions sufficient to controllably activate the quantum dots to controllably regulate the plasma membrane polarization of the functional abnormally polarized light-excitable retinal cone or rod cell by the activated quantum dots, and

monitoring the altered plasma membrane polarization for at least one of a normal polarization state, a repolarized state, a hyperpolarized state, or a hypopolarized state.

8. The method of claim 7 wherein the quantum dots are provided to the vitreous cavity by spraying.

9. The method of claim 7 further comprising a preliminary step of substantially removing vitreous fluid from the vitreous cavity and then performing the method where vitreous fluid is substantially absent from the vitreous cavity.

10. The method of either of claim 1 or claim 7 wherein the desired regulation alleviates a retinal pathology.

11. The method of either claim 1 or claim 7 further comprising spatially regulating the quantum dots in a specific area of the retina.

12. The method of either claim 1 or claim 7 occuring in the absence of an action potential from the activated quantum dots.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2010
From: MINU LLC
To: PEYMAN, GHOLAM A.
Reel/Frame 024371/0290 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2005
From: PEYMAN, GHOLAM A.
To: MINU, LLC
Reel/Frame 016903/0911 →
Continuity (1)
Related Publication 20070028928A1 · Feb 8, 2007